Dragon Pharmaceutical Inc (DRUG)

The AdvisorShares Psychedelics ETF, a fund that primarily invests in the psychedelic drugs sector, is up 31% over the past year. That almost doubles the S&P 500’s 16% gain over the same timeframe.

TheFly reported on February 13 that Baird lowered its price target for DRUG to $126 from $142 and maintained an Outperform rating on the shares.

The psychedelic industry is poised to have a significant "second wave," transforming from a speculative, counterculture-driven movement into a recognized cornerstone of the US healthcare system.

Bright Minds Biosciences Inc. (NASDAQ:DRUG) is a biotechnology company developing highly selective 5-HT2 agonists to treat drug-resistant epilepsy, depression, and other CNS disorders.